New bivalent polio vaccine playing key role in global polio eradication

Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial

A child is immunized in Jalalabad, eastern Afghanistan on a memorable day for polio eradication: 16 December 2009, the first day the groundbreaking bivalent oral polio vaccine was ever used. Cornelia Walther/UNICEF

A head to head trial against current poliovirus vaccines has found that the new bivalent oral vaccine against poliovirus, which targets both the remaining types of poliovirus concurrently, induces a stronger immune response than the traditional trivalent vaccine and a similar immune response to the latest monovalent (monovalent type 1 or monovalent type 3)  vaccines. Furthermore, it is easier to administer, allowing children to be immunised against the two remaining types of wild poliovirus in a single oral dose. These are the conclusions of an Article published Online First in The Lancet.

For details, please go to:
http://www.thelancet.com


Related News

   19/01/2018
The Global Polio Eradication Initiative (GPEI) is extremely saddened that two committed frontline health workers were killed while delivering vaccines in Quetta, Pakistan. We extend our deepest condolences to their family. The delivery of health care is im...
   15/01/2018
To eradicate polio, we need to stop all strains of the virus, including vaccine-derived polioviruses. This short animation explains how these rare virus strains emerge and how to stop them.
   15/01/2018
Update on polio eradication efforts in Afghanistan for December 2017
   09/01/2018
We join Dr Urs Herzog, Rotarian, polio eradicator, National PolioPlus Advocacy Advisor for Rotary Switzerland and polio survivor himself, as he explains the financial costs of the programme and why it is critical that we eradicate every trace of the virus.
   29/12/2017
Johns Hopkins Bloomberg School of Public Health is partnering with institutions in seven countries to help document and disseminate knowledge from the polio programme
   21/12/2017
Carolyn Sein, Technical Officer for the GPEI programme, talks to us about circulating vaccine-derived polioviruses, and the important differences between oral polio vaccine, and inactivated polio vaccine.